Hemophilia patient taking Altuviiio: Joey
Hemophilia patient taking Altuviiio: Joey
“Decreasing infusion frequency means increasing free time
- I'm here for it!”
Joey
Joey
On ALTUVIIIO prophylaxis since May 2023.
On ALTUVIIIO prophylaxis since May 2023.

Hear from Joey

"In my early years, on-demand treatment of bleeding episodes was good enough. But as I got older, I learned that serious issues, like joint bleeds, could occur without me even knowing it. As my treatment needs were changing, I realized that treating prophylactically was a better and more comprehensive approach for my well-being. I switched to prophylaxis treatment and was very pleased with my results.

Over the years, I continued researching treatments and having discussions with my doctor. This eventually led me to ALTUVIIIO, the treatment I use today. I learned that ALTUVIIIO was shown to have higher-for-longer factor levels in the near-normal to normal range for most of the week.
These high sustained factor levels interested me because the data showed they were associated with lower risk of bleeds. ALTUVIIIO also showed a 48-hour half-life in adults, which meant I would only have to infuse once a week for prophylaxis.

That infusion schedule meant the world, especially considering my comprehensive treatment experience. Infusing once a week is a massive improvement for me-something I would never have thought possible years ago."

Joey is a promotional speaker compensated by Sanofi.

"In my early years, on-demand treatment of bleeding episodes was good enough. But as I got older, I learned that serious issues, like joint bleeds, could occur without me even knowing it. As my treatment needs were changing, I realized that treating prophylactically was a better and more comprehensive approach for my well-being. I switched to prophylaxis treatment and was very pleased with my results.

Over the years, I continued researching treatments and having discussions with my doctor. This eventually led me to ALTUVIIIO, the treatment I use today. I learned that ALTUVIIIO was shown to have higher-for-longer factor levels in the near-normal to normal range for most of the week.
These high sustained factor levels interested me because the data showed they were associated with lower risk of bleeds. ALTUVIIIO also showed a 48-hour half-life in adults, which meant I would only have to infuse once a week for prophylaxis.

That infusion schedule meant the world, especially considering my comprehensive treatment experience. Infusing once a week is a massive improvement for me-something I would never have thought possible years ago."

Joey is a promotional speaker compensated by Sanofi.

Hear from more patients

Hemophilia patient taking Altuviiio: David
David
An opera singer on ALTUVIIIO prophylaxis since June 2023
Hemophilia patient Paxton and his caregiver Jenny
Paxton and Jenny
Jenny is Paxton’s mom and caregiver. Paxton is on ALTUVIIIO prophylaxis
Hemophilia patient AJ taking Altuviiio and his caregiver Bonnie
AJ and Bonnie
Bonnie is AJ’s mom and caregiver. AJ is on ALTUVIIIO prophylaxis
Join our Peer Program
Are you currently on ALTUVIIIO? Do you want to share your experience with others? This program may be perfect for you.
Are you currently on ALTUVIIIO? Do you want to share your experience with others? This program may be perfect for you.